Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: A double-blind, cross-over study

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 9, 2003, Pages 883-890

  Pehlivanov, N D ^a,b   Olyaee, M ^a   Sarosiek, I ^a   McCallum, R W ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE;

EID: 0242320349     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01776.x     Document Type: Article

References (17)

1. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11): 825-31.
2. Peghini P, Katz P, Bracy N, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93(5): 763-7.
3. Katz P, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12(12): 1231-4.
4. Hattlebakk J, Katz P, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12(12): 1235-40.
5. Galmiche J, Zerbib F, Ducrotte P, et al. Decreasing oesophageal acid exposure in patients with GERD. A comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 2001; 15(9): 1343-50.
6. Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol 2000; 12(8): 889-97.
7. Johnson LF, DeMeester TR. Twenty-four-hour pH monitoring of the distal esophagus: quantitative measure of gastro-esophageal reflux. Am J Gastroenterol 1974; 62(4): 325-32.
8. Ter RB, Johnston BT, Castell DO. Exclusion of the meal period improves the clinical reliability of esophageal pH monitoring. J Clin Gastroenterol 1997; 25(1): 314-6.
9. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-72.
10. Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening. A comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992; 6(1): 103-11.
11. Adachi K, Fujishiro H, Katsube T, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001; 16(11): 1191-6.
12. Pantoflickova D, Dorta G, Jorno P, et al. Identification of the characteristics influencing the degree of antisecretory activity of PPIs. Gastroenterology 2000; 118(4): A5895 (Abstract).
13. Savarino V, Mela GS, Vigneri S. Nocturnal acid breakthrough in subjects taking PPI b.i.d. Am J Gastroenterol 1999; 94(2): 536-7.
14. Robinson M, Maton PN, Rodriguez S, et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 973-80.
15. Shirai N, Futura T, Moriyama Y, et al. Effect of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15(12): 1929-37.
16. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14(6): 709-14.
17. Pratha V, Karlstadt R, Lynn R, et al. Gastric pH may not be an accurate indicator of gastric acidity. In: ACG Program Book, ACG 66th Annual Scientific Meeting, Las Vegas, NV, USA. October 22-24. 2002. London: ACG. 2002: 303.